News

Critical One Confirms Expiration of Star Minerals Option Deal

Critical One Confirms Expiration of Star Minerals Option Deal

Critical One Energy Inc. Communicates Expiration of Option

TORONTO — Critical One Energy Inc. (formerly Madison Metals Inc.) is announcing an important update regarding its dealings with Star Minerals Limited concerning the Cobra Uranium Project. This update is significant as it affects the future direction of the company and its strategic objectives.

Details of the Expired Agreement

The agreement between Critical One Energy and Star Minerals was aimed at allowing Star Minerals to earn a stake in the Cobra Uranium Project located near the renowned Rossing Uranium Mine. This deal, announced previously, provided Star Minerals with the chance to acquire up to a 51% interest through a structured series of cash payments, share issuances, and essential project expenditures.

Extension Requests and Outcomes

In a development that reflects the complexities of resource project agreements, Star Minerals requested an extension that would push the closing date into early March 2025. However, the company ultimately did not fulfill its obligations, resulting in the expiration of the agreement without Star Minerals acquiring any interest in the project.

Critical One's Position After Expiration

Following the expiration of this agreement, Critical One retains an 85% interest in the Cobra Uranium Project. The company also received a non-refundable deposit of US$40,000, alongside a payment of US$75,000 and 5.3 million common shares from Star Minerals. This outcome highlights Critical One's solid position in managing its resources and ensuring continued investment in projects that align with emerging energy demands.

Overview of Critical One's Strategic Focus

Critical One Energy Inc. positions itself as a forward-looking entity in the world of critical minerals and energy exploration. With a commitment to powering clean energy and innovative technologies, the company is strategically placed to meet the increasing global demand for essential minerals. Critical One's current focus includes significant exploration activities, especially in uranium and antimony, which are pivotal for various technological advancements.

Leadership and Vision

The team behind Critical One combines extensive expertise in energy and mineral sectors, equipping the company to leverage its resources effectively. By focusing on upgrading and promoting high-value projects while exploring partnerships and joint ventures, Critical One aims to drive growth and shareholder value.

Further Information About the Company

For anyone seeking more insights into Critical One Energy Inc.’s operations, details are available on their website. The company actively maintains transparency and engagement with its stakeholders through various communication channels.

For further inquiries, please contact:

Duane Parnham
Executive Chairman & CEO
Critical One Energy Inc.
+1 (416) 489-0092
ir@madisonmetals.ca

Media inquiries:

Adam Bello
Manager, Media & Analyst Relations
Primoris Group Inc.
+1 (416) 489-0092
media@primorisgroup.com

Frequently Asked Questions

What is the Cobra Uranium Project?

The Cobra Uranium Project is a mineral project aimed at uranium extraction, previously under consideration by Star Minerals.

Why did the agreement with Star Minerals expire?

The agreement expired because Star Minerals did not meet its financial and operational commitments.

What interest does Critical One retain in the Cobra Project?

Critical One retains an 85% interest in the Cobra Uranium Project following the expiration of the agreement.

What are the future plans for Critical One?

Critical One aims to further explore and develop its existing mineral resources while seeking strategic partnerships.

How can stakeholders stay informed about Critical One’s developments?

Stakeholders can stay informed by visiting Critical One's website and following their media releases for updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Two Xinjiang Histories Arrive With a Clear State Lens

Updated Category News Views 162

Dusty chronology rarely carries this much present-day weight. Two books released in Beijing on September 2, The History of China's Xinjiang Region and The Religious History in China's Xinjiang Region, are presented as the most comprehensive works on the subject yet produced by Chinese scholars. That is a sizable claim, and it deserves to be read with both attention and a...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 80

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 0

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
TD Pledges $2 Billion to Financial Strength by 2036

Updated Category News Views 83

A Longer-Term Bet on Household Resilience A bank’s community budget rarely grabs the market by the collar, but TD’s new target deserves more than a polite nod. The bank says it will direct $2 billion, or US$1.4 billion, toward helping people build financial strength across North America over the next decade. That is a sizable commitment, even for an institution with...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 59

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 19

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 119

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 126

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 40

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 20

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading

Top 5 Most Recently Viewed Articles

Raphael Bostic's Forecast for Interest Rate Cuts in 2024

Updated Category News Views 139

Fed's Bostic Discusses Future Interest Rate Cuts Atlanta Federal Reserve President Raphael Bostic has recently shared his insights regarding future interest rate adjustments. At a recent event in Atlanta, Bostic indicated that he has projected a further interest rate decrease of 25 basis points this year. This update follows his review of the central bank's recent...

Continue Reading
Boardwalktech Software to Showcase Innovations at Upcoming Event

Updated Category News Views 169

Boardwalktech Software Demonstrates Commitment to Innovation Boardwalktech Software Corp. (TSXV: BWLK) (OTCQB: BWLKF), recognized as a leader in the Intelligent Information Platform sector, has announced that their CEO and Chairman, Andrew Duncan, is set to present at the highly anticipated Planet MicroCap Showcase. This event, in partnership with MicroCapClub, serves as...

Continue Reading
Michael Saylor Advocates for U.S. Leadership in Cryptocurrency

Updated Category News Views 123

Michael Saylor's Vision for Digital Assets Michael Saylor, the co-founder of Strategy Inc. and a prominent advocate for Bitcoin, recently held discussions with key figures in the House Financial Services Committee. His conversations focused on strategies to position the United States as a leading authority in the world of Bitcoin and cryptocurrencies. The Digital Assets...

Continue Reading
Gents Doctor Unveils Insights on Testosterone Therapy and Health

Updated Category News Views 297

Gents Doctor Shares New Insights on Testosterone Therapy Gents Doctor, a well-known male health clinic led by Dr. Majid Sabour, MD, has recently unveiled two important blog posts that explore significant topics related to Testosterone Replacement Therapy (TRT). These posts are designed to inform men who are interested in improving their health through hormone...

Continue Reading
Promising Results from Phase III POLARIS-1 Study of Olverembatinib

Updated Category News Views 233

Exciting Developments in the Treatment of Ph+ ALL At the recent American Society of Hematology (ASH) meeting, cutting-edge research on Olverembatinib, a promising drug from Ascentage Pharma, highlighted its impressive efficacy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The findings from the Phase III...

Continue Reading